Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
Coronavirus
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
On Target
STAT+

In a wily protein that helps cancer spread, researchers see a chance to make immunotherapy more effective

  • Angus Chen

By Angus Chen Feb. 17, 2022

Reprints
On target column illo cancer drug targets
Molly Ferguson for STAT

On Target is a new recurring feature from STAT that dives deep into the most promising drug targets in oncology. 

Of all the wily ways tumors have to turn back attacks from therapies or the immune system, an immune protein called TGF-beta may be one of the most curious.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Angus Chen

Angus Chen

Cancer Reporter

Angus Chen is a cancer reporter at STAT.

Tags

People with terminal cancer need to know they are…
People with terminal cancer need to know they are dying. Doctors shouldn’t withhold that information
Your questions on the new Covid vaccine boosters answered
Your questions on the new Covid vaccine boosters answered
A Q&A with WHO’s Maria Van Kerkhove on Covid…
A Q&A with WHO’s Maria Van Kerkhove on Covid — and fatigue over the pandemic
Pharmalittle: Illumina faces more challenges after winning FTC case;…
Pharmalittle: Illumina faces more challenges after winning FTC case; Novo Nordisk buys Forma Therapeutics
People with terminal cancer need to know they are…
People with terminal cancer need to know they are dying. Doctors shouldn’t withhold that information
Illumina wins case against FTC in bid to hold…
Illumina wins case against FTC in bid to hold onto early cancer detection company Grail

Recommended Stories